FindTrial
Sign In

Evaluation of safety, effectiveness and duration of immunity after vaccination against Covid-19 in patients with autoimmune rheumatic diseases

Safety, effectiveness and duration of immunity after vaccionation against new SARS-COV2 in patients with immunomediated rheumatic diseases

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-108fyykd
Enrollment
Unknown
Registered
2021-04-14
Start date
2021-04-27
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune diseases

Interventions

2000 patients with immune-mediated rheumatic diseases will receive the vaccine against Covid19 and will be followed up for 1 year. The follow-up of the patients will be carried out with visits during
D20.215.894

Sponsors

Universidade Federal de São Paulo
Lead Sponsor
Sociedade Brasileira de Reumatologia
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: rheumatoid arthritis; systemic lupus erythematosus; Sjogren's syndrome; systemic sclerosis; myopathies; vasculitis; spondyloarthritis; both sexes; age above eighteen years; medical indication to vaccinate against covid-19

Exclusion criteria

Exclusion criteria: Immunosuppressed by other causes; HIV; CD4 below two hundred cells; organ transplantation; primary immunodeficiency; cancer; myasthenia gravis; thymoma; absence or surgical removal of the thymus; pregnancy; history of severe adverse reaction to any vaccine previously administered

Design outcomes

Primary

MeasureTime frame
To evaluate the safety, effectiveness and duration of response to vaccines against Sars-Cov-2, in patients with immune-mediated Rheumatic Diseases, in the short and long term.—

Secondary

MeasureTime frame
To evaluate the effectiveness, duration and immunogenicity of the response to vaccines against Sars-Cov-2—

Countries

Brazil

Contacts

Public ContactEdgard dos Reis Neto
edgard.torres@unifesp.br+551155764239

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 2, 2026